Imunon Seeks Shareholder Approval for Significant Equity Incentive Plan Expansion
IMNN is trading near its 52-week low of $2.52 (12% above the low) on light trading volume (0.1× avg).
Summary
Imunon, Inc. has filed a definitive proxy statement seeking shareholder approval to increase its equity incentive plan by 1,000,000 shares, representing a potential dilution of over 25% to current outstanding shares, to aid in talent retention amidst a 'going concern' warning.
Key Events · Financing and Capital Events · IMNN
-
Shareholder Meeting Scheduled
The Annual Meeting of Stockholders is scheduled for June 16, 2026, where key proposals will be voted upon.
-
Proposed Equity Incentive Plan Expansion
Shareholders will vote on an amendment to the 2018 Stock Incentive Plan to increase the aggregate number of shares available for awards by 1,000,000, raising the total limit to 1,265,004 shares.
-
Significant Potential Dilution
The additional 1,000,000 shares represent a potential dilution of approximately 25.10% of the company's current outstanding shares (3,983,342 shares as of April 17, 2026).
-
Strategic Rationale for Talent Retention
The company states this expansion is essential to attract, motivate, and retain key employees, aligning with its need to address a previously disclosed 'going concern' warning.
Analysis · IMNN · Life Sciences
Imunon, Inc. is seeking shareholder approval to significantly expand its 2018 Stock Incentive Plan by adding an additional 1,000,000 shares. This proposed increase represents a potential dilution of approximately 25.10% relative to the current outstanding shares. The company emphasizes that this expansion is crucial for attracting, motivating, and retaining key employees, which is particularly vital given its previously disclosed 'going concern' status. While dilutive, the ability to offer competitive equity compensation is presented as essential for the company's operational continuity and long-term success, potentially mitigating the negative impact of dilution by addressing critical talent retention needs.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMNN was trading at $2.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11M. The 52-week trading range was $2.52 to $41.22. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.